BSBiren Saraiya

Biren Saraiya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Biren Saraiya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Communication Skills for Discussing Treatment Options When Chemotherapy Has Failed

    by Biren Saraiya, Robert Arnold, James A. Tulsky

    Palliative care is defined as care for symptoms throughout the disease trajectory delivered along with disease-modifying therapies, whether the patient has curable or incurable cancer. Patients have unique informational and emotional needs at each point in their disease trajectories. To meet each patient's needs, oncologists can follow a road map presented here for discussing treatment options that include palliative care. Oncologists can learn what patients need cognitively by eliciting perceptions about cancer and its treatment before giving any bad news. Emotional reactions can be anticipated and handled with empathy to reduce patient distress. After patients' emotions have been addressed and they are ready to discuss treatment options, oncologists can establish shared treatment goals. These shared treatment goals may need to be negotiated, including resolving conflicts between perceptions and knowledge. Finally, based on these goals, the oncologist can offer patient-centered recommendations and help establish a treatment plan.


  • Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors

    by Biren Saraiya, Rashmi Chugh, Vassiliki Karantza, Janice Mehnert, Rebecca A. Moss, Nelli Savkina, Mark N. Stein, Laurence H. Baker, Thomas Chenevert, Elizabeth A. Poplin

    Purpose: In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib. Experimental Design: Imatinib was administered at 400 mg daily on days 1–5, 8–12 and 15–19. Gemcitabine was started at 600 mg/m2 at a rate of 10 mg/min on days 3 and 10 and docetaxel at 30 mg/m2 on day 10, on a 21-day cycle. Diffusion and dynamic contrast-enhanced perfusion MRI was performed in selected patients. Results: Twenty patients with relapsed/refractory solid tumors were enrolled in this IRB-approved study. The mean age was 64, and mean ECOG PS was 1. Two patients were evaluated by diffusion/perfusion MRI. After two grade 3 hematological toxicities at dose level 1, the protocol was amended to reduce the dose of imatinib. MTDs were 600 mg/ m2 on days 3 and 10 for gemcitabine, 30 mg/ m2 on day 10 for docetaxel, and 400 mg daily on days 1–5 and 8–12 for imatinib. Dose limiting toxicities after one cycle were neutropenic fever, and pleural and pericardial effusions. The best response achieved was stable disease, for six cycles, in one patient each with mesothelioma and non small cell lung cancer (NSCLC) at the MTD. Two patients with NSCLC had stable disease for four cycles. Discussion: An unexpectedly low MTD for this triplet was identified. Our results suggest drug-drug interactions that amplify toxicities with little evidence of improved tumor control.


  • Open Access

    End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy

    by Biren Saraiya, Susan Bodnar-Deren, Elaine Leventhal, Howard Leventhal

    The goal of end‐of‐life (EoL) planning is to provide individuals with tools to control their financial and healthcare decisions when they are incapacitated. When an elderly patient is diagnosed with advanced cancer, the possible treatment options are palliative care with curative intent or prolongation of life or palliative care only. Treatment of cancer in elderly patients creates a significant array of monetary and symptom burdens. The question is whether advance care planning, part of EoL planning, allows patients' families and communities to control and reduce these burdens. Although the number of patients completing advance directives has increased in recent years, there are multiple barriers to the implementation of patients' wishes, such as limited knowledge of patient wishes by proxy and physician and inadequate communication regarding prognosis. In this article, the authors propose that improvements in patient decision making and clinical practice can reduce the burden of symptoms for patients if clinicians gain a better understanding of patients' models and expectations respecting the longer term consequences of diagnosis and treatment. This understanding can arise from improved information exchange and constant updating of the information as the disease and treatment evolves. Clinicians also need better prognostication tools and better training in effective communication skills to elicit patient goals and to make appropriate recommendations. Cancer 2008;113(12 suppl):3540–7. © 2008 American Cancer Society.